article · PLoS Medicine

Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study

Hira Tanvir
Gavin Churchyard
Mave
Tomos O. Prys-Jones
Mark Hatherill
Rein M. G. J. Houben
Tom Sumner
Kirankumar Rade
Katherine C. Horton
Roel Bakker
Rebecca A. Clark
Richard G. White

2026Open accessUniversity of Cape Town

Abstract

Our modelling estimates that the population impact of new TB vaccines may depend on efficacy against infectious asymptomatic disease. TB vaccine trials should include analyses of participant sputum samples (collected during or at the end of trials and analysed at the end of trials) to enable better estimates of the potential value of new TB vaccines against infectious asymptomatic disease.

Research topics

Tuberculosis Research and Epidemiology
Immune responses and vaccinations
Malaria Research and Control

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1371/journal.pmed.1004595

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.